Inhibition of TNF-α Oncogene Expression by Artemisia Annua L. Extract Against Pioglitazone Side Effects in Male Albino Mice

Author:

Botrous Silvia,Elmaghraby Ayaat,El-Achy Samar,Mustafa Yehia,Badr Effat,Haggag Amany,Abdel-Rahman SalahORCID

Abstract

AbstractPioglitazone (Actos) is one of the most recent oral antidiabetic drugs for treating the second type of diabetes mellitus as a common chronic and lifelong disease, but with harmful side effects. The objective of this study is to evaluate the effectiveness of Artemisia annua L. extract against the Actos drug side effects in the male albino mice. In present study, the use of Actos drug alone induced hepatotoxicity, renal inflammation, hematological disorders and bladder cancer, which are manifested by biochemical abnormalities and histopathological changes, moreover, the severity of toxicity depends on its dose. In contrast, the concurrent treatment with both Actos drug (45 mg/kg) and Artemisia extract (4 g/kg) was effective against the harmful side effects of the Actos drug. Where, the biochemical, hematological and histopathological investigations showed that the hepatotoxicity, renal inflammation, hematological disorders and histopathological changes were improved using combination of Actos and Artemisia extract. In addition, the results of TNF-ɑ oncogene expression levels in bladder tissues were significantly decreased by about 99.99% using the mix of both Actos drug and Artemisia extract. In conclusion, these findings reveal that the Artemisia annua extract on TNF-ɑ oncogene expression level is very significant and effective natural product against harmful side effects of pioglitazone which associated with an increased risk of incident bladder cancer among people, but for application more studies must be achieved in that field.

Funder

City of Scientific Research and Technological Applications

Publisher

Springer Science and Business Media LLC

Subject

Molecular Biology,Applied Microbiology and Biotechnology,Biochemistry,Bioengineering,Biotechnology

Reference29 articles.

1. Mizrachi, E., & Bernel-Mizrachi, C. (2007). Diabetes mellitus and related disorders. In D. H. Cooper, A. J. Krainik, S. J. Lubner, & H. E. L. Reno (Eds.), Washington manual of medical therapeutics (32nd ed., pp. 600–623). Philadelphia: Wolters Kluwer/Lippincott Williums and Wilkins.

2. Desouza, C. V., & Shivaswamy, V. (2010). Pioglitazone in the treatment of type 2 diabetes: Safety and efficacy review. Clinical Medicine Insights. Endocrinology and Diabetes, 3, 43–51.

3. Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., & Berria, R. (2006). A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England Journal of Medicine, 355, 2297–2307.

4. Nolte, M. S. (2009). Pancreatic hormones and antidiabetic drugs. In B. G. Katzung, S. B. Masters, & A. J. Trevor (Eds.), Basic and clinical pharmacology (11th ed., pp. 727–751). New Delhi: Tata McGraw Hill Education Private Limited.

5. Schernthaner, G., Matthews, D. R., Charbonnel, B., Hanefeld, M., & Brunetti, P. (2004). Quartet study group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A doubleblind, randomized trial. Journal of Clinical Endocrinology and Metabolism, 89, 6068–6076.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3